Neuroradiology. 2026 Jan 17. doi: 10.1007/s00234-025-03882-w. Online ahead of print.
ABSTRACT
PURPOSE: To assess the diagnostic performance of tumor blood volume (TBV) derived from T1 dynamic contrast-enhanced (DCE) MRI and compare it with ADC and SUVmax in distinguishing recurrence from post-treatment changes.
METHODS: This retrospective study included 73 patients with 75 focal contrast-enhancing lesions identified on surveillance MRI. Normalized TBV (nTBVmean) was calculated from high temporal resolution DCE-MRI using the spinal cord as a reference. The 3D ROI analysis of ADCmean and SUVmax values were obtained from DWI and 18F-FDG-PET/CT, respectively. Diagnostic performances were evaluated using multivariate logistic regression analyses, with area under the receiver operating characteristic curve (AUROC) comparisons.
RESULTS: Among the 75 lesions, 38 were recurrence and 37 were post-treatment changes. ADCmean and SUVmax were significantly different between groups (p < 0.001), while nTBVmean was higher in recurrence without statistical significance (p = 0.11). The AUROC of ADCmean, SUVmax, and nTBVmean were 0.94, 0.88, and 0.60 respectively. The combination of ADCmean and SUVmax yielded the highest AUROC (0.99), with ADCmean remaining the most robust predictor. TBV offered complementary value when ADC maps were degraded by susceptibility artifacts.
CONCLUSIONS: ADCmean and SUVmax showed excellent performance in differentiating recurrence from post-treatment changes. TBV maps may offer complementary diagnostic value in cases with compromised ADC quality due to artifacts.
PMID:41546724 | DOI:10.1007/s00234-025-03882-w
